The Trump administration's aggressive tariff policy is reshaping the pharmaceutical manufacturing landscape. Generic drugmaker Sandoz faces mounting pressure to relocate production operations to the United States or absorb substantial import duties. As negotiations commence with government officials, the Swiss company evaluates the economic feasibility of domestic manufacturing expansion. This protectionist strategy aims to strengthen American pharmaceutical independence, though industry experts warn of potential consequences for drug accessibility and affordability across the healthcare sector.

Summary auto-generated by AI from the original publisher's content. Editorial standards.